These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 14507279)

  • 1. Impact of HCV 3.0 EIA relative to HCV 2.0 EIA on blood-donor screening.
    Tobler LH; Stramer SL; Lee SR; Masecar BL; Peterson JE; Davis EA; Andrews WE; Brodsky JP; Kleinman SH; Phelps BH; Busch MP
    Transfusion; 2003 Oct; 43(10):1452-9. PubMed ID: 14507279
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative yield of HCV RNA testing in blood donors screened by 2.0 versus 3.0 antibody assays.
    Galel SA; Strong DM; Tegtmeier GE; Holland PV; Kuramoto IK; Kemper M; Pietrelli L; Gallarda J
    Transfusion; 2002 Nov; 42(11):1507-13. PubMed ID: 12421226
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Follow-up of six blood donors highlights the complementary role and limitations of hepatitis C virus antibody and nucleic acid amplification tests.
    Hyland C; Seed CR; Kiely P; Parker S; Cowley N; Bolton W
    Vox Sang; 2003 Jul; 85(1):1-8. PubMed ID: 12823724
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acute hepatitis C virus seroconversion in a Scottish blood donor: HCV antigen is not comparable with HCV nucleic acid amplification technology screening.
    Dow BC; Munro H; Buchanan I; Ferguson K; Davidson F; Lycett C; Jarvis M; Cleland A; Petrik J; Lumley S; MacLean A
    Vox Sang; 2004 Jan; 86(1):15-20. PubMed ID: 14984555
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Routine HCV PCR screening of blood donations to identify early HCV infection in blood donors lacking antibodies to HCV.
    Hitzler WE; Runkel S
    Transfusion; 2001 Mar; 41(3):333-7. PubMed ID: 11274586
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Integration of nucleic acid amplification test results into hepatitis C virus supplemental serologic testing algorithms: implications for donor counseling and revision of existing algorithms.
    Kleinman SH; Stramer SL; Brodsky JP; Caglioti S; Busch MP
    Transfusion; 2006 May; 46(5):695-702. PubMed ID: 16686836
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Significance of the signal-to-cutoff ratios of anti-hepatitis C virus enzyme immunoassays in screening of Chinese blood donors.
    Ren FR; Lv QS; Zhuang H; Li JJ; Gong XY; Gao GJ; Liu CL; Wang JX; Yao FZ; Zheng YR; Zhu FM; Tiemuer MH; Bai XH; Shan H
    Transfusion; 2005 Nov; 45(11):1816-22. PubMed ID: 16271110
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of low cost peptide-based anti-hepatitis C virus screening and confirmatory assays: comparison with commercially available tests.
    Palacios A; Taylor L; Haue L; Luftig RB; Visoná KA
    J Med Virol; 1999 Jul; 58(3):221-6. PubMed ID: 10447416
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Performance of second- and third-generation RIBAs for confirmation of third-generation HCV EIA-reactive blood donations. Retrovirus Epidemiology Donor Study.
    Tobler LH; Lee SR; Stramer SL; Peterson J; Kochesky R; Watanabe K; Quan S; Polito A; Busch MP
    Transfusion; 2000 Aug; 40(8):917-23. PubMed ID: 10960517
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-specific and specific anti-HCV results correlated to age, sex, transaminase, rhesus blood group and follow-up in blood donors.
    Caspari G; Gerlich WH; Beyer J; Schmitt H
    Arch Virol; 1997; 142(3):473-89. PubMed ID: 9349294
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Age, sex and transaminase dependency of specific and nonspecific results from enzyme immunoassays for antibodies to hepatitis C virus and follow-up of blood donors.
    Caspari G; Gerlich WH; Beyer J; Schmitt H
    Infusionsther Transfusionsmed; 1995 Aug; 22(4):208-19. PubMed ID: 7496119
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Investigation of an algorithm for anti HCV EIA reactivity in blood donor screening in Turkey in the absence of nucleic acid amplification screening.
    Karakoc AE; Berkem R; Irmak H; Demiroz AP; Yenicesu I; Ertugrul N; Arslan Ö; Kemahli S; Yilmaz S; Ozcebe O; Kara A; Ozet G; Acikgoz ZC; Acikgoz T
    Transfus Apher Sci; 2017 Oct; 56(5):732-737. PubMed ID: 28941882
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnosis of hepatitis C virus in Brazilian blood donors using a reverse transcriptase nested polymerase chain reaction: comparison with enzyme immunoassay and recombinant protein immunoblot assay.
    Gonçales NS; Costa FF; Vassallo J; Gonçales FL
    Rev Inst Med Trop Sao Paulo; 2000; 42(5):263-7. PubMed ID: 11058936
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of antibodies to hepatitis C virus in blood donors and their relationship to surrogate markers.
    Hugo T; Wüst T; Beeser HP
    Beitr Infusionsther; 1992; 30():49-52. PubMed ID: 1284765
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Seronegative hepatitis C virus infection in Polish blood donors-Virological characteristics of index donations and follow-up observations.
    Grabarczyk P; Kubicka-Russel D; Kopacz A; Liszewski G; Sulkowska E; Zwolińska P; Madaliński K; Marek M; Szabelewska M; Świątek E; Laskus T; Radkowski M
    J Med Virol; 2020 Mar; 92(3):339-347. PubMed ID: 31670401
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A pilot study for screening blood donors in Taiwan by nucleic acid amplification technology: detecting occult hepatitis B virus infections and closing the serologic window period for hepatitis C virus.
    Li L; Chen PJ; Chen MH; Chak KF; Lin KS; Tsai SJ
    Transfusion; 2008 Jun; 48(6):1198-206. PubMed ID: 18422856
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lookback on donors who are repeatedly reactive on first-generation hepatitis C virus assays:justification and rational implementation.
    Tobler LH; Tegtmeier G; Stramer SL; Quan S; Dockter J; Giachetti C; Busch MP
    Transfusion; 2000 Jan; 40(1):15-24. PubMed ID: 10644807
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatitis C virus in blood samples from volunteer donors.
    Zhang HY; Kuramoto IK; Mamish D; Sazama K; Holland PV; Zeldis JB
    J Clin Microbiol; 1993 Mar; 31(3):606-9. PubMed ID: 8384627
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of two second-generation anti-hepatitis C virus ELISA on 21431 US blood donor samples.
    Anderson SC; Hathaway T; Kuramoto IK; Holland PV; Gilcher R; Koch T; Hojvat S
    J Viral Hepat; 1995; 2(1):55-61. PubMed ID: 7493295
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of hepatitis C virus (HCV) core-specific antibody suggests occult HCV infection among blood donors.
    Quiroga JA; Avellón A; Bartolomé J; Andréu M; Flores E; González MI; González R; Pérez S; Richart LA; Castillo I; Alcover J; Palacios R; Carreño V; Echevarría JM
    Transfusion; 2016 Jul; 56(7):1883-90. PubMed ID: 27185049
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.